Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257943 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
A Phase 1 study of Lice; Head Lice, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 413
- Enrollment target
- 1
- Study location
NCT03257943 is a Phase 1 study of Lice; Head Lice that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 413 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03257943, a Phase 1 study of Lice; Head Lice, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 413 participants
- Enrollment target
- 1
- Study location
Study Summary
A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%
Conditions Studied
Interventions
- DRUG Ivermectin Lotion, 0.5%
- DRUG SKLICE (ivermectin) Lotion, 0.5%
- DRUG Vehicle of the Test product
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2017-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257943
The ClinicalTrials.gov registry entry for NCT03257943 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lice; Head Lice appearing as the primary indexed condition, and to 3 interventions - of which Ivermectin Lotion, 0.5% is the first listed.
NCT03257943 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03257943 about?
NCT03257943 is a clinical study titled "A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%". A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%
What is the current status of trial NCT03257943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 413 participants. The study started on 2017-03-20. Estimated completion is 2017-08-18.
What conditions does trial NCT03257943 study?
This clinical trial studies the following conditions: Lice; Head Lice.
What interventions are being tested in trial NCT03257943?
The interventions under investigation include: Ivermectin Lotion, 0.5% (DRUG), SKLICE (ivermectin) Lotion, 0.5% (DRUG), Vehicle of the Test product (DRUG).
Who is sponsoring clinical trial NCT03257943?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03257943 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.